Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Key Takeaways A social media giant faltered on Thursday, Oct. 30, 2025, as artificial intelligence costs piled up, while a ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...

Moderna may look appealing right now, given the company's high cash balance and extensive drug pipeline. However, as Moderna's cash burn dilemma persists, the company's net value will likely keep ...

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know. What To Know: Tuesday’s rally was driven by the release of positive ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Shares of Moderna Inc. fell ...